This compound is a cytotoxic agent designed for use in antibody-drug conjugates, featuring a complex macrocyclic structure with multiple functional groups including amides, ethers, and a halogen atom. It is primarily employed as a pharmaceutical raw material in the manufacturing of targeted cancer therapeutics.
Alcance del contenido: La información de esta página se refiere a la identificación química y a los contextos de suministro industrial, investigación y producción. No constituye una afirmación terapéutica, un consejo médico ni instrucciones de uso de medicamentos.
¿Adquiriendo o suministrando este compuesto?
Publique su inventario o una solicitud de compra
CAS 1375089-56-7
Mertansine
antibody-drug conjugate payload
Maytansinoid DM3
antibody-drug conjugate payload
[(1S,2R,3S,5S,6S,16Z,18Z,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[6-[[[(2S)-2-[[(2R)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]propanoyl]amino]propanoyl]amino]propanoyl]amino]methylsulfanyl]hexanoyl-methylamino]propanoate
antibody-drug conjugate linker payload
Ravtansine
tubulin-binding maytansinoid anticancer agent
Bpc 157
investigational therapeutic peptide
(+)-2'-Deoxy-3'-thia-5-fluorocytidine
active pharmaceutical ingredient
Dioxopromethazine
active pharmaceutical ingredient
Gemigliptin tartrate sesquihydrate
active pharmaceutical ingredient
[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl-methylamino]propanoate
UGBPANNIQRLRII-RJPAQOSPSA-N
C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCCCCN5C(=O)C=CC5=O)C)\C)OC)(NC(=O)O2)O